MedTrace Logo

Intranasal Steroids and Oxymetazoline in Allergic Rhinitis

NCT00584987 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2013-12-17

Study results available
· View outcomes & findings →

Summary

We hypothesize that once daily use of oxymetazoline will not cause significant rhinitis medicamentosa and that the combination of fluticasone furoate plus oxymetazoline leads to faster relief of nasal congestion secondary to perennial allergic rhinitis than the use of fluticasone furoate alone.

Conditions

  • Allergic Rhinitis

Interventions

DRUG

Fluticasone furoate

2 puffs of each nasal spray in each nostril in the pm

DRUG

Placebo Fluticasone furoate

2 puffs of each nasal spray in each nostril in the pm

DRUG

Oxymetazoline

2 puffs of each nasal spray in each nostril in the pm

DRUG

Placebo Oxymetazoline

2 puffs of each nasal spray in each nostril in the pm

Sponsors & Collaborators

Principal Investigators

  • Robert M Naclerio, MD · University of Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00584987 on ClinicalTrials.gov